Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook

The cell & gene therapy bioanalytical testing services market in Saudi Arabia is expected to reach a projected revenue of US$ 6.2 million by 2030. A compound annual growth rate of 3.8% is expected of Saudi Arabia cell & gene therapy bioanalytical testing services market from 2024 to 2030.
Revenue, 2023 (US$M)
$4.8
Forecast, 2030 (US$M)
$6.2
CAGR, 2024 - 2030
3.7%
Report Coverage
Saudi Arabia

Saudi Arabia cell & gene therapy bioanalytical testing services market, 2018-2030 (US$M)

Saudi

Related Markets

Saudi Arabia cell & gene therapy bioanalytical testing services market highlights

  • The Saudi Arabia cell & gene therapy bioanalytical testing services market generated a revenue of USD 4.8 million in 2023 and is expected to reach USD 6.2 million by 2030.
  • The Saudi Arabia market is expected to grow at a CAGR of 3.8% from 2024 to 2030.
  • In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
  • Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.


Cell & gene therapy bioanalytical testing services market data book summary

Market revenue in 2023USD 4.8 million
Market revenue in 2030USD 6.2 million
Growth rate3.8% (CAGR from 2023 to 2030)
Largest segmentBioavailability & bioequivalence studies
Fastest growing segmentBioavailability & Bioequivalence Studies
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type
Key market players worldwideIQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC


Other key industry trends

  • In terms of revenue, Saudi Arabia accounted for 0.9% of the global cell & gene therapy bioanalytical testing services market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, Saudi Arabia cell & gene therapy bioanalytical testing services market is projected to lead the regional market in terms of revenue in 2030.
  • South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 5.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell & Gene Therapy Bioanalytical Testing Services Market Companies

Name Profile # Employees HQ Website

Saudi Arabia cell & gene therapy bioanalytical testing services market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.


Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.42% in 2023. Horizon Databook has segmented the Saudi Arabia cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.


In 2023, Saudi Arabia accounted for 27.7% of the MEA market. This growth can be attributed to several factors, including an increase in the number of approved gene therapy products & biological therapies and growing public awareness of the advantages of effective biopharmaceutical solutions.

For example, in January 2024, Vertex Pharmaceuticals announced the clearance of CASGEVY (exagamglogene autotemcel [exa-cel]), the first CRISPR/Cas9 gene-edited medicine for treating Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia in patients aged 12 and above.

CASGEVY is the first medication assessed under the SFDA's breakthrough medicines program after the company was given approval by the Saudi SFDA. It is a form of genome editing technology called CRISPR/Cas9-based cellbased gene therapy. CRISPR/Cas9 technology is used to modify the genomes of hematopoietic stem cells in patients.

Reasons to subscribe to Saudi Arabia cell & gene therapy bioanalytical testing services market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Saudi Arabia cell & gene therapy bioanalytical testing services market databook

  • Our clientele includes a mix of cell & gene therapy bioanalytical testing services market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Saudi Arabia cell & gene therapy bioanalytical testing services market size, by test type, 2018-2030 (US$M)

Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook Share, 2023 & 2030 (US$M)

Saudi Arabia cell & gene therapy bioanalytical testing services market size, by test type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more